Loading…
2 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Clinic-LJ | Healthcare Services | 9.1% | 48th pct | 268 |
| LJ Da Ko - Tuberkulozis… | Healthcare Services | -9.7% | 13th pct | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | Clinic-LJ | LJ Da Ko - Tuberkulozis… |
|---|---|---|
| Margins | ||
| Gross Margin | 27.5% | 10.8% |
| EBITDA Margin | 9.1% | -9.7% |
| EBITDAR | 1,417 | -315 |
| EBITDAR Margin | 9.1% | -9.7% |
| EBIT Margin | 9.1% | -22.0% |
| Net Profit Margin | 7.2% | -34.7% |
| Operating Expense % of Sales | 18.4% | 20.5% |
| Returns | ||
| Return on Assets (ROA) | 9.9% | -22.2% |
| Return on Equity (ROE) | 22.1% | -269.2% |
| ROIC [EBIT / Invested Capital] | 16.0% | -21.0% |
| Leverage & debt balances | ||
| Debt-to-Assets | 34.1% | 60.2% |
| Debt-to-Equity | 0.77x | 7.30x |
| Debt-to-EBITDA | 2.75x | N/A |
| Equity-to-Assets | 44.6% | 8.2% |
| Net Debt | 3,766 | 2,975 |
| Cash & Equivalents | 129 | 83 |
| Total Debt | 3,895 | 3,058 |
| Liquidity & working capital | ||
| Current Ratio | 2.78x | 0.71x |
| Quick Ratio | 2.35x | 0.71x |
| Cash Ratio | 0.05x | 0.05x |
| Total Current Assets | 6,876 | 1,135 |
| Total Current Liabilities | 2,471 | 1,593 |
| Inventory | 1,074 | N/A |
| Trade Receivables | 3,323 | 995 |
| Trade Payables | 1,687 | 856 |
| Net Working Capital | 4,405 | -457 |
| Net Working Capital % of Revenue | 28.2% | -14.1% |
| Trade Working Capital | 2,710 | 139 |
| Trade Working Capital % of Revenue | 17.4% | 4.3% |
| Change in Trade Working Capital | N/A | N/A |
| Turnover & efficiency | ||
| Inventory Turnover | 10.52x | N/A |
| Days Inventory Outstanding (DIO) | 34.7 | N/A |
| Receivables Turnover | 4.69x | 3.26x |
| Days Sales Outstanding (DSO) | 77.8 | 111.9 |
| Payables Turnover | 6.70x | 3.38x |
| Days Payable Outstanding (DPO) | 54.5 | 107.9 |
| Cash Conversion Cycle | 58.0 days | 4.0 days |
| Asset Turnover | 1.37x | 0.64x |
| Cash flow & dividends | ||
| Operating Cash Flow | 1,746 | N/A |
| Free Cash Flow (OCF − Capex proxy) | 1,746 | N/A |
| Cash Conversion (OCF / EBITDA) | 123.2% | N/A |
| Dividends Declared | 0 | N/A |
| Dividend Payout Ratio | 0.0% | N/A |